- Home
- PRLD vs VTSI Comparison
PRLD vs VTSI Comparison
Compare PRLD & VTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- VTSI
- Stock Information
- Founded
- PRLD 2016
- VTSI 1993
- Country
- PRLD United States
- VTSI United States
- Employees
- PRLD N/A
- VTSI N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- VTSI Miscellaneous manufacturing industries
- Sector
- PRLD Health Care
- VTSI Consumer Discretionary
- Exchange
- PRLD Nasdaq
- VTSI Nasdaq
- Market Cap
- PRLD 73.7M
- VTSI 75.9M
- IPO Year
- PRLD 2020
- VTSI N/A
- Fundamental
- Price
- PRLD $0.68
- VTSI $4.31
- Analyst Decision
- PRLD Strong Buy
- VTSI Strong Buy
- Analyst Count
- PRLD 2
- VTSI 2
- Target Price
- PRLD $4.50
- VTSI $13.00
- AVG Volume (30 Days)
- PRLD 272.4K
- VTSI 80.3K
- Earning Date
- PRLD 05-06-2025
- VTSI 05-13-2025
- Dividend Yield
- PRLD N/A
- VTSI N/A
- EPS Growth
- PRLD N/A
- VTSI N/A
- EPS
- PRLD N/A
- VTSI 0.12
- Revenue
- PRLD $7,000,000.00
- VTSI $26,350,819.00
- Revenue This Year
- PRLD N/A
- VTSI $14.89
- Revenue Next Year
- PRLD N/A
- VTSI N/A
- P/E Ratio
- PRLD N/A
- VTSI $35.92
- Revenue Growth
- PRLD N/A
- VTSI N/A
- 52 Week Low
- PRLD $0.63
- VTSI $3.88
- 52 Week High
- PRLD $6.80
- VTSI $17.68
- Technical
- Relative Strength Index (RSI)
- PRLD 41.40
- VTSI 33.08
- Support Level
- PRLD $0.71
- VTSI $3.92
- Resistance Level
- PRLD $0.76
- VTSI $4.73
- Average True Range (ATR)
- PRLD 0.07
- VTSI 0.37
- MACD
- PRLD 0.01
- VTSI -0.06
- Stochastic Oscillator
- PRLD 18.75
- VTSI 25.42
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About VTSI VirTra Inc.
VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company includes installation, training, limited warranties, service agreements and related support. The company sells and supports use of force training and marksmanship firearms training systems and accessories for law enforcement, military or civilian use. The product line of the company includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire and other accessories.